We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.
Apremilast is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers. We are standing out in launching the only generic version of Apremilast in the form of a starter kit (10 mg, 20 mg, and 30 mg) additionally to bottles of 30 mg tablets. This allows the product to be taken gradually to the recommended dosage, facilitating the work of physicians and pharmacists and improving the patient experience.
The product has been developed and produced in TIEFENBACHER GROUP´s own state-of-the-art facilities in India and is marketed by our partner, a well-established Canadian pharmaceutical company.
With this early market entry TIEFENBACHER PHARMACEUTICALS achieves significant savings for the international health care systems and enables patients in Canada a better affordable access to a life-improving treatment.
AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on: www.aet.eu
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
Further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets can be found on can be found on www.tiefenbacher.com or you can contact us info@aet.eu
